在生物原始IBD患者中,生物药物诱导疗法后的临床反应是否预测两年内治疗失败? - 使用两个丹麦研究人口
Ken Lund1, Jan Nielsen1,2, Caroline Theilgaard Thorarinsson1
1Center for Clinical Epidemiology, Odense University Hospital.
Journal of clinical gastroenterology
|October 10, 2025
概括
在炎症性肠病 (IBD) 患者的生物诱导疗法后的疾病活动与更糟糕的结果有关,包括治疗变化和手术. 监测这种活动可以预测IBD管理中的未来不良事件.
科学领域:
- 胃肠病学和肝病学
- 临床免疫学临床免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 生物药物对炎症性肠病 (IBD) 有效,但有些患者对诱导疗法没有充分的反应.
- 诱导后的持续性疾病活动需要进一步调查其长期影响.
研究的目的:
- 调查生物诱导疗法后疾病活性与炎症性肠病 (IBD) 患者的治疗失败终点之间的关联.
- 为了确定治疗失败的早期指标,以优化IBD管理策略.
主要方法:
- 一项丹麦队列研究,涉及两个生物原始IBD群体 (Bio-IBD和全国注册).
- 在诱导治疗后120天内,具有和没有疾病活性的患者的比较.
- 考克斯的比例危险回归模型被用来分析与治疗失败终点的关联.
主要成果:
- 在9961名IBD患者中,33.2% (生物IBD) 和13.3% (全国) 的IBD患者在诱导后观察到活跃的疾病.
- 活跃疾病显著增加了转换生物治疗,IBD手术,住院和使用皮质类固醇的风险.
- 对治疗失败的调整后危险比为1.33和2.69在各自的人群中,突出显示了显著的风险增加.
结论:
- 在IBD生物诱导治疗后的疾病活动是不良结果的重要预测因素,包括治疗修改和与疾病相关的并发症.
- 临床医生可以利用诱导后疾病活动作为预后标记,预测和管理IBD患者未来的不良事件.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
780
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
780
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
703
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
703
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
1.1K
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
1.1K
Inflammatory Bowel Disease IV: Pharmacological Management
1.1K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
1.1K
Measurement of Bioavailability: Pharmacodynamic Methods
1.0K
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
1.0K
Bioequivalence of Drugs: Drugs with Multiple Indications
230
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
230


